One analyst reiterated his pessimistic view of the pharmaceutical titan's future.

The company has increased its payouts over the past five years despite significant challenges.

Pfizer PFE and AbbVie ABBV are leading U.S. drugmakers with strong positions across multiple therapeutic areas. Oncology ...

Pfizer Inc. (NYSE:PFE) is one of the 8 Cheap Large Cap Stocks to Buy Now. On April 9, 2026, BofA lowered the price target on ...

PFE holds above key SMAs with a 2026 rally, but weak guidance, COVID declines, and patent risks cloud its recovery outlook ...

Pfizer is behind Eli Lilly and Novo Nordisk in the GLP-1 race, but long-term investors shouldn't count the company out.

Pfizer (NYSE: PFE) is a high-yielding stock that's trading at a low valuation. The problem is, it's been that way for some time now. The stock's lack of movement in one direction or another seems to ...

Pfizer Inc. shares ticked up modestly Tuesday as investors weighed fresh positive oncology data against the pharmaceutical ...

Pfizer (NYSE: PFE) stock gave up 3.3% through 10:50 a.m. ET Tuesday despite delivering an earnings beat this morning. Analysts forecast the pharmaceuticals giant would earn $0.57 per share on $16.8 ...

If I am a Pfizer Inc. (PFE) investor (I used to be, nonetheless), I should have been "elated" at PFE's recent performance against the market, while still getting rewarded with a forward yield that ...

Pfizer Inc PFE shares are trading lower on Tuesday after the company and its COVID-19 vaccine partner paused an updated-shot ...